In NSCLC, exon 18 p.G727A, exon 20 p.G776V, and exon 21 p.V842I mutations in the HER2 receptor kinase domain have been recorded in the Foundation Medicine or cBioPortal dataset and recognized as oncogenic [9]; however, their responses to HER2 inhibitors remain unclear. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.